Navigation Links
MedImmune Licenses Reverse Genetics Technology to Hungary's Omninvest for Use in Influenza Vaccine Development and Production
Date:10/16/2008

Second Agreement Signed in Third Quarter of 2008 Expands Worldwide

Application of Cutting-Edge Influenza Vaccine Technology

GAITHERSBURG, Md., Oct. 16 /PRNewswire/ -- MedImmune announced today that it has licensed its proprietary reverse genetics intellectual property to Omninvest, a Hungarian research and manufacturing company, to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only with segments of the virus's genome. This announcement marks the second agreement of this kind that MedImmune signed in the third quarter of 2008.

"Omninvest has demonstrated decades of commitment to providing protection against influenza, and we commend their commitment to donate some of their product to the World Health Organization (WHO) stockpile for distribution among developing nations," said MedImmune's Jonathan Klein-Evans, vice president, intellectual property. "MedImmune is pleased to license our reverse genetics technology to Omninvest as we have done previously to five other influenza vaccine manufacturers."

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of key patent estates for use of the reverse genetics technology in human influenza vaccines, MedImmune has offered other influenza vaccine manufacturers non-exclusive licenses to these intellectual property estates for use in manufacturing seasonal or pandemic vaccines.

In a first for any influenza vaccine manufacturer, MedImmune applied the reverse genetics process to the development of its seasonal live, attenuated nasal spray influenza vaccine for the 2008-2009 season.

Since December of 2006, MedImmune has licensed its reverse genetics technology to CSL Limited of Australia, sanofi pasteur, Novartis, GlaxoSmithKline and BIKEN of Japan.

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
2. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
3. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
4. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
5. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
6. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
7. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
8. Seneca Valley High School Student Receives Science Award From MedImmune
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... ... the adulterants which pose the most likely threat to their products at the ... year. , IFT's annual food expo attracts over 20,000 attendees representing food ...
(Date:6/20/2017)... San Francisco, CA (PRWEB) , ... June 20, ... ... with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, announces ... International Conference in San Diego, California. Dave Johnson, PhD, CEO of GigaGen, will ...
(Date:6/19/2017)... ... ... A colony of healthy honey bees is like a superorganism--individual bees provide ... containing nutrients necessary for growth and survival. Better nutrition gives the colony a strong ... a decline in honey bee health. Sick and weakened bees diminish the colony's resiliency, ...
(Date:6/15/2017)... ... June 15, 2017 , ... New ... farmers new options for managing Palmer amaranth and other broadleaf weeds resistant to ... precautions are necessary. Auxin herbicides are known to drift and to cause harm ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):